Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions

被引:93
作者
Kornmann, M
Ishiwata, T
Beger, HG
Korc, M
机构
[1] UNIV CALIF IRVINE,MED SCI INST C240,DEPT MED BIOL CHEM & PHARMACOL,IRVINE,CA 92697
[2] UNIV ULM,DEPT GEN SURG,D-89075 ULM,GERMANY
关键词
fibroblast growth factor-5; fibroblast growth factor receptor splice variant; in situ hybridization; mitogenic signaling; pancreatic cancer; protein kinases;
D O I
10.1038/sj.onc.1201307
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fibroblast growth factor (FGF)-1 and -2 are overexpressed in human pancreatic cancer. In this study the role of FGF-5 in human pancreatic cancer was investigated, as FGF-5 has a classical signal sequence for secretion not found in FGF-1 or -2. Northern blot analysis with a 306 bp FGF-5 cDNA revealed the presence of 4.0 kb and 1.6 kb FGF-5 mRNA transcripts in both normal and cancerous pancreatic tissues. Densitometric analysis indicated that 4.0 kb and 1.6 kb FGF-5 mRNA transcripts levels were increased 2.4- and 2.7-fold in the cancers by comparison with normal tissues, respectively (P<0.002, P<0.0001). Immunohistochemistry and in situ hybridization demonstrated that FGF-5 localized in the cancer cells, stromal fibroblast and inflitrating macrophages. FGF-5 mRNA was also detected in COLO-357 human pancreatic cancer cells. Furthermore, secreted FGF-5 protein was present in conditioned medium of COLO-357 cells. Exogeneous FGF-5 (0.37 nM) increased the growth of COLO-357 cells by 48% (P<0.0001) and increased mitogen-activated protein kinase activity. COLO-357 cells expressed the IIIc isoform of the type I FGF receptor, the preferred FGF receptor for FGF-5. These observations suggest that FGF-5 may participate in autocrine and paracrine pathways promoting pancreatic cancer cell growth in vivo.
引用
收藏
页码:1417 / 1424
页数:8
相关论文
共 42 条
[1]   KERATINOCYTE GROWTH-FACTOR FUNCTIONS IN EPITHELIAL INDUCTION DURING SEMINAL-VESICLE DEVELOPMENT [J].
ALARID, ET ;
RUBIN, JS ;
YOUNG, P ;
CHEDID, M ;
RON, D ;
AARONSON, SA ;
CUNHA, GR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (03) :1074-1078
[2]  
ALTORKI N, 1993, CANCER-AM CANCER SOC, V72, P649, DOI 10.1002/1097-0142(19930801)72:3<649::AID-CNCR2820720305>3.0.CO
[3]  
2-L
[4]  
[Anonymous], 1983, J IMMUNOL METH
[5]   A NOVEL FORM OF FGF RECEPTOR-3 USING AN ALTERNATIVE EXON IN THE IMMUNOGLOBULIN DOMAIN-III [J].
AVIVI, A ;
YAYON, A ;
GIVOL, D .
FEBS LETTERS, 1993, 330 (03) :249-252
[6]   THE FGF FAMILY OF GROWTH-FACTORS AND ONCOGENES [J].
BASILICO, C ;
MOSCATELLI, D .
ADVANCES IN CANCER RESEARCH, 1992, 59 :115-165
[7]   BIOSYNTHESIS OF HUMAN FIBROBLAST GROWTH FACTOR-5 [J].
BATES, B ;
HARDIN, J ;
ZHAN, X ;
DRICKAMER, K ;
GOLDFARB, M .
MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (04) :1840-1845
[8]  
Burgess W. H., 1996, P154
[9]  
CLEMENTS DA, 1993, ONCOGENE, V8, P1311
[10]   CLONING AND EXPRESSION OF 2 DISTINCT HIGH-AFFINITY RECEPTORS CROSS-REACTING WITH ACIDIC AND BASIC FIBROBLAST GROWTH-FACTORS [J].
DIONNE, CA ;
CRUMLEY, G ;
BELLOT, F ;
KAPLOW, JM ;
SEARFOSS, G ;
RUTA, M ;
BURGESS, WH ;
JAYE, M ;
SCHLESSINGER, J .
EMBO JOURNAL, 1990, 9 (09) :2685-2692